Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Early Pipeline Case Study

- PMLiVE

Results from Global Pharmaceutical Customer Experience survey

UCB and J&J Innovative Medicine come out on top, while customer experience is in a state of flux

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by FDA to treat uncontrolled COPD

Approximately 300,000 patients in the US will be eligible for the therapy

- PMLiVE

Roche’s Genentech acquires Regor Pharmaceuticals’ CDK inhibitors for $850m upfront

One of the candidates included in the deal has already shown promise in a phase 1a advanced breast cancer study

- PMLiVE

J&J and Legend share long-term results for Carvykti in phase 3 multiple myeloma study

More than 35,000 people are expected to be diagnosed with the blood cancer in the US this year

- PMLiVE

Bristol Myers Squibb announces positive data for Sotyktu in moderate-to-severe psoriasis

At least 100 million people worldwide are affected by the immune-mediated disease

- PMLiVE

Strategy execution – ensuring it all fits together

Effective brand strategies are like a well-made jigsaw but they can end up looking nothing like the picture that was agreed on

- PMLiVE

Successful Education at ESC

With World Heart Day just having passed (29th September), Medscape wants to take the opportunity to look back and recap what was accomplished at ESC 2024.  At this year’s event,...

Medscape Education

- PMLiVE

How women are revolutionising rare disease

Women have played a crucial role in rare disease awareness and better care, overcoming gender biases and systemic challenges to drive progress in this often-overlooked field.

Medscape Education

- PMLiVE

FDA approves IntraBio’s Aqneursa to treat Niemann-Pick disease type C patients

The rare lysosomal storage disorder affects approximately one in every 100,000 to 120,000 births

- PMLiVE

Roche’s injectable C5 inhibitor PiaSky recommended by NICE for rare blood disorder PNH

Paroxysmal nocturnal haemoglobinuria affects approximately 1.59 per 100,000 people in the UK

- PMLiVE

Johnson & Johnson’s Yuvanci granted EC approval to treat pulmonary arterial hypertension

Yuvanci is now the only single tablet combination therapy for PAH patients in Europe

- PMLiVE

‘Causes That Count, Health’ report – key issues affecting global health

The report focuses on the physical and mental health issues that matter most to people around the world

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links